pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,272 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints891BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7585Rare Disease1872Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • AI sepsis tools face timing challenges, says STAT AI Prognosis newsletter
    The latest STAT AI Prognosis newsletter notes that current sepsis detection algorithms sometimes require data from future time points, which is unrealistic. The piece highlights how such quirks in…
    STAT · 3mo agoNeutral↗ source
  • Septuagenarian begins family-medicine residency at 72 after 45-year nursing career
    Dawn Zuidgeest-Craft, a former neonatal nurse practitioner, finally entered medical school at age 69 after decades of clinical work and personal life events. She graduated in 2025 and, despite not…
    STAT · 3mo agoPositive↗ source
← prev
page 91 of 131
next →
fda recalls69
fda medwatch60
fda press38
1172
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA review
GSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
Endpoints · 3mo agoDealPositive↗ source
  • Ending federally funded animal testing could stall xenotransplantation breakthroughs
    Transplant surgeon Joshua Mezrich argues that recent moves to end federally funded animal testing could impede the development of xenotransplantation, a field that aims to use pig organs for human…
    STAT · 3mo agoRegulatoryNegative↗ source
  • GSK to acquire cancer-focused biotech Nuvalent for $10.6 billion
    GSK announced it will acquire Nuvalent, a biotech that develops targeted cancer therapies, in a transaction valued at $10.6 billion. The purchase price translates to $124 per Nuvalent share, a 26%…
    STAT · 3mo agoDealPositive↗ source
  • GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA review
    GSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • U.S. drug shortages drop 23% but average duration climbs to over five years, analysis shows
    The latest U.S. Pharmacopeia analysis reports that the total number of prescription drug shortages fell by 23% last year, marking the second year of decline and the lowest level since 2017. Despit…
    STAT · 3mo agoNegative↗ source
  • Trump’s health-care affordability czar targets hospitals, raises concerns over suppressed alcohol study
    The piece reports that the Trump administration’s health‑care affordability czar has begun scrutinizing hospitals, signaling a new push to control costs and improve price transparency. The czar’s…
    STAT · 3mo agoRegulatoryNegative↗ source
  • FDA approves first new sunscreen ingredient in over 25 years
    The U.S. Food and Drug Administration has cleared a new sunscreen active called bemotrizinol, the first novel ingredient to receive approval in more than a quarter‑century. The agency said the che…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Grace Science warns FDA bottleneck threatens ultra-rare gene therapy progress
    Grace Science, a biotech focused on ultra-rare diseases, has been developing a gene-therapy candidate that appeared close to regulatory approval. The company, co-founded by Nobel laureate Carolyn…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Garner Health secures $100 million funding, valuation climbs to $2.7 billion
    Garner Health announced a $100 million financing round that pushes its post‑money valuation to $2.7 billion. The capital raise was completed last month and was led by a group of venture investors.…
    Endpoints · 3mo agoDealPositive↗ source
  • Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioTools
    Treeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipeline
    GSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…
    STAT · 3mo agoDealNeutral↗ source
  • Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s program
    On June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…
    Endpoints · 3mo agoDealNeutral↗ source
  • Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trial
    Gilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy. In a separate study, Merck reported that its Pha…
    Endpoints · 3mo agoNeutral↗ source
  • GSK to acquire cancer drug developer Nuvalent for $10.6 billion
    GSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion. The acquisition is intended to broaden GSK’s oncology portfolio an…
    STAT · 3mo agoDealNeutral↗ source
  • Dexcom trial shows continuous glucose monitors improve outcomes across diabetes types
    Dexcom reported results from a randomized controlled trial that evaluated its continuous glucose monitoring system in a wide range of people with diabetes. The study compared the CGM device to stan…
    STAT · 3mo agoPositive readoutPositive↗ source
  • WuXi AppTec re-added to Pentagon list of firms linked to Chinese military
    WuXi AppTec has been placed again on the Pentagon's updated list of companies that have ties to the Chinese military, according to a June 9, 2026 report. The inclusion marks renewed scrutiny of th…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Trump health-care czar touts $510 billion Medicaid cut, warns hospitals of financial strain
    At a Healthcare Financial Management Association conference in National Harbor, Maryland, the Trump administration’s newly appointed health-care affordability czar addressed hospital finance leader…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Former USAID Ebola adviser says lessons from 2014 are fading as new outbreak spreads in DRC and Uganda
    In October 2014 Susan Reichle served as a counselor to USAID in Washington, D.C., when the CDC launched its largest ever Ebola response. She contrasts that crisis with the current outbreak in the…
    STAT · 3mo agoNeutral↗ source
  • Biopharma workers earned $116,648 on average in 2025, about 30% above S&P 500 peers
    The Endpoints News pay analysis found that the average biopharma employee earned $116,648 in 2025. This figure reflects compensation across the sector for that year. Compared with the broader mark…
    Endpoints · 3mo agoPositive↗ source
  • ADA ejects five diabetes experts for distributing editorial criticizing NIH research cuts
    Security personnel removed five diabetes researchers from the American Diabetes Association's annual meeting in New Orleans after they handed out copies of an editorial that condemned recent federa…
    STAT · 3mo agoNegative↗ source
  • Eli Lilly's 340B claims data deadline passes, sparking potential new dispute
    Eli Lilly set a deadline for hospitals to submit 340B drug‑pricing program claims data under its new policy. The deadline has now passed, and the company has not indicated what actions it will tak…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Federal alcohol study finds low-level drinking may raise disease risk, faces political pushback
    STAT’s Morning Rounds reported that a federally commissioned study on alcohol’s health effects was published today in an independent journal. The researchers concluded that even modest alcohol cons…
    STAT · 3mo agoRegulatoryNeutral↗ source